Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.

The polyglutamine (polyQ) diseases consist of nine neurodegenerative diseases in which a polyQ tract expansion leads to protein misfolding and subsequent aggregation. Even when the causative proteins have the same length polyQ tract, there are differences in the severity and age of disease onset which implicate the polyQ flanking sequences as modulators of disease. Recent studies on the polyQ proteins ataxin-1, ataxin-3 and huntingtin exon-1 have shown that the flanking domains have an intrinsic ability to aggregate. This complex behavior leads to a multi-stage aggregation mechanism which we have termed multi-domain misfolding. In multi-domain misfolding, a flanking domain to the polyQ tract plays an early role in aggregation, before the contribution of the polyQ tract. A number of factors including the stability, dynamics and amyloidogenicity of the flanking domain modulate the impact on polyQ tract aggregation as well as any protein-protein interactions it undertakes. In this review, we examine the recent data in support of this novel mechanism of protein aggregation.

[1]  Stephen P Bottomley,et al.  The Two-stage Pathway of Ataxin-3 Fibrillogenesis Involves a Polyglutamine-independent Step* , 2006, Journal of Biological Chemistry.

[2]  P. Loll,et al.  An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel β-fibrils , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Manjit,et al.  Neurology , 1912, NeuroImage.

[4]  Amy L. Robertson,et al.  The structural impact of a polyglutamine tract is location-dependent. , 2008, Biophysical journal.

[5]  Frederic Rousseau,et al.  How evolutionary pressure against protein aggregation shaped chaperone specificity. , 2006, Journal of molecular biology.

[6]  H. Zoghbi,et al.  Molecular and clinical correlations in spinocerebellar ataxia type I: evidence for familial effects on the age at onset. , 1994, American journal of human genetics.

[7]  Dalaver H. Anjum,et al.  Polyglutamine disruption of the huntingtin exon1 N-terminus triggers a complex aggregation mechanism , 2009, Nature Structural &Molecular Biology.

[8]  Luis Velazquez,et al.  Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset. , 2005, Brain : a journal of neurology.

[9]  Zoya Ignatova,et al.  In-cell Aggregation of a Polyglutamine-containing Chimera Is a Multistep Process Initiated by the Flanking Sequence* , 2007, Journal of Biological Chemistry.

[10]  Michele Vendruscolo,et al.  Prediction of aggregation-prone regions in structured proteins. , 2008, Journal of molecular biology.

[11]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[12]  S. Radford,et al.  HDX-ESI-MS Reveals Enhanced Conformational Dynamics of the Amyloidogenic Protein β2-Microglobulin upon Release from the MHC-1 , 2009, Journal of the American Society for Mass Spectrometry.

[13]  Lisa D. Cabrita,et al.  Polyglutamine Expansion in Ataxin-3 Does Not Affect Protein Stability , 2004, Journal of Biological Chemistry.

[14]  Ronald Wetzel,et al.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Fischbeck,et al.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy , 1991, Nature.

[16]  I. Kanazawa,et al.  SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. , 2001, Human molecular genetics.

[17]  Giuseppe Nicastro,et al.  Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3. , 2004, Journal of molecular biology.

[18]  X. Estivill,et al.  Presymptomatic analysis of spinocerebellar ataxia type 1 (SCA1) via the expansion of the SCA1 CAG-repeat in a large pedigree displaying anticipation and parental male bias. , 1993, Human molecular genetics.

[19]  Reinhard Pahl,et al.  Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. , 2007, Journal of molecular biology.

[20]  Annalisa Pastore,et al.  Solution structure of polyglutamine tracts in GST‐polyglutamine fusion proteins , 2002, FEBS letters.

[21]  C. Dobson,et al.  Rationalization of the effects of mutations on peptide andprotein aggregation rates , 2003, Nature.

[22]  Osamu Onodera,et al.  Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. , 2008, Human molecular genetics.

[23]  Michelle K. M. Chow,et al.  Structural and functional analysis of the Josephin domain of the polyglutamine protein ataxin-3. , 2004, Biochemical and biophysical research communications.

[24]  G. Feldman,et al.  Juvenile onset Huntington disease resulting from a very large maternal expansion , 2005, American journal of medical genetics. Part A.

[25]  Sandra Macedo-Ribeiro,et al.  Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3. , 2005, Journal of molecular biology.

[26]  A. Pastore,et al.  Polyglutamine is not all: the functional role of the AXH domain in the ataxin-1 protein. , 2005, Journal of molecular biology.

[27]  Susan Lindquist,et al.  Flanking sequences profoundly alter polyglutamine toxicity in yeast. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Y. Agid,et al.  Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion , 1997, Nature Genetics.

[29]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[30]  A. Komar,et al.  Stability, folding, dimerization, and assembly properties of the yeast prion Ure2p. , 2001, Biochemistry.

[31]  William B. Dobyns,et al.  Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel , 1997, Nature Genetics.

[32]  H. Paulson,et al.  The Role of Protein Composition in Specifying Nuclear Inclusion Formation in Polyglutamine Disease* , 2001, The Journal of Biological Chemistry.

[33]  Stephen P Bottomley,et al.  Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. , 2007, Journal of molecular biology.

[34]  I. Kanazawa,et al.  DNA analysis in hereditary dentatorubral-pallidoluysian atrophy , 1995, Neurology.

[35]  James F. Gusella,et al.  Molecular genetics: Unmasking polyglutamine triggers in neurodegenerative disease , 2000, Nature Reviews Neuroscience.

[36]  O. Onodera,et al.  Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation , 2001, Neuroreport.

[37]  Ronald Wetzel,et al.  Oligoproline effects on polyglutamine conformation and aggregation. , 2006, Journal of molecular biology.

[38]  Shigenobu Nakamura,et al.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1 , 1994, Nature Genetics.

[39]  B. Brais,et al.  PABPN1 polyalanine tract deletion and long expansions modify its aggregation pattern and expression. , 2008, Experimental cell research.

[40]  D. Merry,et al.  Soluble Androgen Receptor Oligomers Underlie Pathology in a Mouse Model of Spinobulbar Muscular Atrophy* , 2007, Journal of Biological Chemistry.

[41]  M. Saraste,et al.  FEBS Lett , 2000 .

[42]  S. Brahmachari,et al.  Identification of a novel 45 repeat unstable allele associated with a disease phenotype at the MJD1/SCA3 locus , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[43]  J. Olson,et al.  Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.

[44]  Annalisa Pastore,et al.  The AXH domain adopts alternative folds the solution structure of HBP1 AXH. , 2005, Structure.

[45]  James R. Burke,et al.  Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display Screening* , 2000, The Journal of Biological Chemistry.

[46]  Fabrizio Chiti,et al.  Prevention of amyloid‐like aggregation as a driving force of protein evolution , 2007, EMBO reports.

[47]  Seho Kim,et al.  Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. , 2008, Journal of molecular biology.

[48]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[49]  A. Komar,et al.  Structural Characterization of Saccharomyces cerevisiae Prion-like Protein Ure2* , 1999, The Journal of Biological Chemistry.

[50]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[51]  Stephen P Bottomley,et al.  Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease. , 2004, Journal of molecular biology.

[52]  S Kobayashi,et al.  A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? , 1999, Human molecular genetics.

[53]  H. Zoghbi,et al.  Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the infantile phenotype , 1998, Neurology.